Raed Suleiman, MD
Pulmonary Disease · Gastonia, NCNPI 1730657115
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,825 of the $194,778 with a category attached, or 90.3%. AstraZeneca accounts for 97.0% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2021 at $64,056 and has fallen 59.7% since, to $25,845 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $443.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$189K
- GSK$1K
- Olympus Corporation Of The Americas$632
- Boehringer Ingelheim$603
- Insmed, Inc.$409
- Actelion Pharmaceuticals US, Inc.$276
- plus $3K from 31 others
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$175,82590%
- Travel & lodging$8,8425%
- Food & beverage$9,9525%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 236 | $189,011 |
| GSK | 44 | $1,093 |
| Olympus Corporation Of The Americas | 2 | $632 |
| Boehringer Ingelheim | 21 | $603 |
| Insmed, Inc. | 16 | $409 |
| Actelion Pharmaceuticals US, Inc. | 11 | $276 |
| Grifols USA, LLC | 14 | $257 |
| Electromed, Inc. | 17 | $247 |
| Jazz Pharmaceuticals Inc. | 2 | $178 |
| Amgen | 4 | $172 |
| Verona Pharma, Inc. | 4 | $170 |
| Regeneron Healthcare Solutions, Inc. | 6 | $167 |
| Sanofi | 6 | $161 |
| Mylan Specialty L.p. | 8 | $161 |
| Genentech, Inc. | 1 | $129 |
| Merck | 6 | $121 |
| Inspire Medical Systems, Inc. | 2 | $112 |
| United Therapeutics Corporation | 4 | $90 |
| Pulmonx Corporation | 2 | $85 |
| Harmony Biosciences LLC | 4 | $84 |
| Novo Nordisk | 1 | $73 |
| Pfizer | 3 | $68 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $63 |
| Nabriva Therapeutics, PLC | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Philips North America LLC | 3 | $39 |
| CSL Behring | 1 | $34 |
| Advanced Respiratory, Inc | 2 | $31 |
| Baxter Healthcare | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Viatris Specialty LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $14 |
| AbbVie | 1 | $14 |
| Resmed Corp | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$194,778 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 433 | $320,057 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $50,235 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $37,290 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $17,918 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 107 | $17,000 |
| Spiriva RespimatTiotropium Bromide | 31 | $16,221 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $15,548 |
| Wixela InhubFluticasone Propion/Salmeterol | 93 | $9,293 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $6,661 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 155 | $3,626 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,519 |
| Montelukast Sodium | 169 | $944 |
| Pantoprazole Sodium | 49 | $254 |
| Fluticasone Propionate | 20 | $204 |
| Levocetirizine Dihydrochloride | 26 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,093 | $375,265552 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $189,011 | $56,897103 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $603 | $31,76954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Gastonia
- Mikell JarrattGastonia$45K
- Emeka EziriGastonia$28K
- Anup BanerjeeGastonia$19K
- Jay HendlerGastonia$17K
- Azeem ElahiGastonia$17K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.